CA2234877A1 - Herpesvirus vectors and their uses - Google Patents

Herpesvirus vectors and their uses Download PDF

Info

Publication number
CA2234877A1
CA2234877A1 CA002234877A CA2234877A CA2234877A1 CA 2234877 A1 CA2234877 A1 CA 2234877A1 CA 002234877 A CA002234877 A CA 002234877A CA 2234877 A CA2234877 A CA 2234877A CA 2234877 A1 CA2234877 A1 CA 2234877A1
Authority
CA
Canada
Prior art keywords
cells
human
virus
gene
malignant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002234877A
Other languages
English (en)
French (fr)
Inventor
Stephen Charles Inglis
Malcolm Keith Brenner
Michael Edward Griffith Boursnell
Dagmar Dilloo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenova Research Ltd
St Jude Childrens Research Hospital
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9525906.5A external-priority patent/GB9525906D0/en
Application filed by Individual filed Critical Individual
Publication of CA2234877A1 publication Critical patent/CA2234877A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002234877A 1995-10-19 1996-10-21 Herpesvirus vectors and their uses Abandoned CA2234877A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US564995P 1995-10-19 1995-10-19
US60/005,649 1995-10-19
GBGB9525906.5A GB9525906D0 (en) 1995-12-19 1995-12-19 Herpesvirus vectors
GB9525906.5 1995-12-19

Publications (1)

Publication Number Publication Date
CA2234877A1 true CA2234877A1 (en) 1997-04-24

Family

ID=26308326

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002234877A Abandoned CA2234877A1 (en) 1995-10-19 1996-10-21 Herpesvirus vectors and their uses

Country Status (4)

Country Link
EP (1) EP0856062A2 (de)
JP (1) JPH11513565A (de)
CA (1) CA2234877A1 (de)
WO (1) WO1997014808A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
JP3923505B2 (ja) * 2003-08-29 2007-06-06 株式会社ウイルス医科学研究所 Ｈｈｖ−６由来の組換ウイルスベクター、その製造方法、それを用いた宿主細胞の形質転換方法、それにより形質転換された宿主細胞およびそれを用いた遺伝子治療方法
EP1694852B1 (de) 2003-11-17 2010-10-13 Crusade Laboratories Limited Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
GB2421025A (en) * 2004-12-09 2006-06-14 Oxxon Therapeutics Ltd HSV vaccination vectors
US8257712B2 (en) * 2008-07-03 2012-09-04 Saint Louis University Virus-expressing host costimulation molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918616D0 (en) * 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
JP3895366B2 (ja) * 1990-09-25 2007-03-22 キャンタブ ファーマシューティカルズ リサーチ リミティド ウィルス ワクチン
US7223411B1 (en) * 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
JP4044131B2 (ja) * 1992-07-31 2008-02-06 プレジデント アンド フェローズ オブ ハーバード カレッジ ヘルペスウイルスワクチン
AU696336B2 (en) * 1993-03-19 1998-09-10 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. HSV) as vaccine

Also Published As

Publication number Publication date
MX9802999A (es) 1998-09-30
EP0856062A2 (de) 1998-08-05
WO1997014808A2 (en) 1997-04-24
JPH11513565A (ja) 1999-11-24
WO1997014808A3 (en) 1997-07-24

Similar Documents

Publication Publication Date Title
AU711121B2 (en) Viral preparations, vectors, immunogens, and vaccines
JP5492418B2 (ja) ウイルス関連疾患を予防するためのウイルス遺伝子産物およびワクチン接種の方法
DE69834022T2 (de) Fusionproteine für intra- und interzelluläre transport und deren verwendungen
US6344445B1 (en) Herpes virus vectors and their uses
US6051428A (en) Rapid production of autologous tumor vaccines
JPH11502222A (ja) 遺伝子供給用ベクター
CN101928695B (zh) 生产免疫细胞的方法及诱发产生免疫作用细胞的方法
CA2234877A1 (en) Herpesvirus vectors and their uses
Hu et al. Varicella-zoster virus open reading frame 47 (ORF47) protein is critical for virus replication in dendritic cells and for spread to other cells
CN109810197B (zh) 用于高效扩增nk的人工抗原递呈细胞及其构建方法
AU5533896A (en) Transplantation of genetically modified cells having low levels of class I MHC proteins on the cell surface
CN115286698B (zh) 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
US20030083289A1 (en) Herpesvirus vectors and their uses
EP3967706A1 (de) Aav-mutante zur effizienten infektion von stützzellen
Zurkova et al. Attenuation of vaccinia virus by the expression of human Flt3 ligand
AU763297B2 (en) Herpesvirus vectors and their uses
Giavedoni et al. Expression of IL-18 by SIV does not modify the outcome of the antiviral immune response
Smith et al. Introduction of new genetic material into human myeloid leukemic blast stem cells by retroviral infection
MXPA98002999A (en) Vectors of the herpes virus and its u
AU4445599A (en) Viral preparations, vectors, immunogens, and vaccines
Wang et al. Immune modulation of human B lymphocytes by gene transfer with recombinant Epstein–Barr virus amplicons
Zurkova et al. Research Attenuation of vaccinia virus by the expression of human Flt3 ligand
EA041619B1 (ru) Способ продуцирования человеческих антигенспецифических т-лимфоцитов
MXPA99006583A (en) Fusion proteins for intracellular and intercellular transport and their uses

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead